All 8 investigational A/H1N1 vaccine formulations were well tolerated , and rapidly induced high antibody titers which met all of the Center for Biologics Evaluation and Research ( CBER ) and Committee for Medicinal Products for Human Use ( CHMP ) licensure criteria 3 weeks after one dose .